Oyster Point Pharma Inc. (OYST)
$11.17
$0.00 (0.00%)As on 12-Jan-2023 09:30EDT
Market cap
$300 Mln
Revenue (TTM)
$20 Mln
P/E Ratio
--
P/B Ratio
2.4
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-177 Mln
-
ROE
-3.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-2
-
Debt to Equity
-4.2
-
Book Value
$--
-
EPS
$-6.6
-
Face value
--
-
Shares outstanding
26,844,300
5 Years Aggregate
CFO
$-210.34 Mln
EBITDA
$-235.15 Mln
Net Profit
$-239.99 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Oyster Point Pharma (OYST)
| 0.0 | 0.4 | 68.7 | -27.5 | -25.3 | -- | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2022
|
2021
|
2020
|
|---|---|---|---|
|
Oyster Point Pharma (OYST)
| -38.8 | -3.0 | -23.0 |
|
S&P Small-Cap 600
| -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Oyster Point Pharma (OYST)
|
11.2 | 299.9 | 19.6 | -176.7 | -839.0 | -- | -- | 2.4 |
| 15.0 | 521.5 | 68.2 | -29.0 | -35.9 | -88.3 | -- | 18.0 | |
| 0.5 | 7.9 | 1.7 | -30.4 | -1,803.2 | -184.5 | -- | 1.0 | |
| 36.0 | 1,218.6 | 0.0 | -61.6 | -- | -33.1 | -- | 7.0 |
Shareholding Pattern
View DetailsAbout Oyster Point Pharma (OYST)
As of January 3, 2023, Oyster Point Pharma, Inc. was acquired by Viatris Inc. Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat... ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey. Read more
-
Pres, CEO & Director
Dr. Jeffrey Nau MMS, Ph.D.
-
Pres, CEO & Director
Dr. Jeffrey Nau MMS, Ph.D.
-
Headquarters
Princeton, NJ
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Oyster Point Pharma (OYST)
What is the current share price of Oyster Point Pharma Inc (OYST) Today?
The share price of Oyster Point Pharma Inc (OYST) is $11.17 (NASDAQ) as of 12-Jan-2023 09:30 EDT. Oyster Point Pharma Inc (OYST) has given a return of -25.28% in the last 3 years.
What is the current PB & PE ratio of Oyster Point Pharma Inc (OYST)?
Since, TTM earnings of Oyster Point Pharma Inc (OYST) is negative, P/E ratio is not available.
The P/B ratio of Oyster Point Pharma Inc (OYST) is 2.39 times as on 02-Feb-2023, a 49 discount to its peers’ median range of 4.72 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-4.75
|
4.80
|
|
2020
|
-6.90
|
2.61
|
|
2019
|
-7.48
|
2.49
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
What is the 52 Week High and Low of Oyster Point Pharma Inc (OYST)?
The 52-week high and low of Oyster Point Pharma Inc (OYST) are Rs -- and Rs -- as of 13-Jun-2026.
What is the market cap of Oyster Point Pharma Inc (OYST)?
Oyster Point Pharma Inc (OYST) has a market capitalisation of $ 300 Mln as on 02-Feb-2023. As per SEBI classification, it is a Small Cap company.
Should I invest in Oyster Point Pharma Inc (OYST)?
Before investing in Oyster Point Pharma Inc (OYST), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.